Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Naree Eiamsirikit"'
Autor:
Gonzague Jourdain, Sophie Le Cœur, Nicole Ngo-Giang-Huong, Patrinee Traisathit, Tim R Cressey, Federica Fregonese, Baptiste Leurent, Intira J Collins, Malee Techapornroong, Sukit Banchongkit, Sudanee Buranabanjasatean, Guttiga Halue, Ampaipith Nilmanat, Nuananong Luekamlung, Virat Klinbuayaem, Apichat Chutanunta, Pacharee Kantipong, Chureeratana Bowonwatanuwong, Rittha Lertkoonalak, Prattana Leenasirimakul, Somboon Tansuphasawasdikul, Pensiriwan Sang-A-Gad, Panita Pathipvanich, Srisuda Thongbuaban, Pakorn Wittayapraparat, Naree Eiamsirikit, Yuwadee Buranawanitchakorn, Naruepon Yutthakasemsunt, Narong Winiyakul, Luc Decker, Sylvaine Barbier, Suporn Koetsawang, Wasna Sirirungsi, Kenneth McIntosh, Sombat Thanprasertsuk, Marc Lallemant, PHPT-3 study team
Publikováno v:
PLoS Medicine, Vol 10, Iss 8, p e1001494 (2013)
BackgroundViral load (VL) is recommended for monitoring the response to highly active antiretroviral therapy (HAART) but is not routinely available in most low- and middle-income countries. The purpose of the study was to determine whether a CD4-base
Externí odkaz:
https://doaj.org/article/34088c5dc0be4ad7831a7675568d645b
Autor:
Nicole Ngo-Giang-Huong, Gonzague Jourdain, Billy Amzal, Pensiriwan Sang-a-gad, Rittha Lertkoonalak, Naree Eiamsirikit, Somboon Tansuphasawasdikul, Yuwadee Buranawanitchakorn, Naruepon Yutthakasemsunt, Sripetcharat Mekviwattanawong, Kenneth McIntosh, Marc Lallemant, Program for HIV Prevention and Treatment (PHPT) study group
Publikováno v:
PLoS ONE, Vol 6, Iss 11, p e27427 (2011)
WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs), i.e. nevirapine or efavirenz, with lamivudine or emtricitabine, plus zidovudine or tenofovir. F
Externí odkaz:
https://doaj.org/article/ec8cfed01951462fb579c9ad34cd653f
Autor:
Chureeratana Bowonwatanuwong, Panita Pathipvanich, Prattana Leenasirimakul, Kosit Tantinam, Rittha Lertkoonalak, Somboon Tansuphasawasdikul, Naruepon Yutthakasemsunt, Pacharee Kantipong, Prateung Liampongsabuddhi, Rattakarn Paramee, Nuananong Luekamlung, Isabelle Heard, Chaiwat Putiyanun, Nicole Ngo-Giang-Huong, Sinart Prommas, Rucha Kongpanichkul, Sophie Le Coeur, Sunida Panna, Aram Limtrakul, Diane Le Pluart, Nantasak Chotivanich, Virat Klinbuayaem, Pensiriwan Sang-a-gad, Céline Gallot, Sudanee Buranabanjasatean, Florence Brunet-Possenti, Tristan Delory, Myrtille Prouté, Guttiga Halue, Pakorn Wittayapraparat, Florence Fayard, Alexandre Blake, Samreung Rangdaeng, Wanmanee Matanasarawut, Naree Eiamsirikit, Métrey H. Tiv, Pornnapa Suriyachai, Prapap Yuthavisuthi, Kevin Zarca, Gonzague Jourdain, Fadia Dib, Tapnarong Jarupanich, Suchart Thongpaen, Nusra Puarattana-Aroonkorn, Thomas Althaus, Alice Desbiolles, Sookchai Theansavettrakul, Marc Lallemant, Apichat Chutanunta, Sukit Banchongkit
Publikováno v:
Journal of Infection
Journal of Infection, 2017, 74 (5), pp.501-511. ⟨10.1016/j.jinf.2017.02.007⟩
Journal of Infection, 2017, 74 (5), pp.501-511. ⟨10.1016/j.jinf.2017.02.007⟩
International audience; OBJECTIVES: To estimate the prevalence and factors associated with Human Papillomavirus (HPV) infection, HPV genotypes and cytological/histological high-grade (HSIL+/CIN2+) lesions. METHODS: We conducted a cross-sectional stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::972f99ad92503c627ae659eee659e607
https://pubmed.ncbi.nlm.nih.gov/28254419
https://pubmed.ncbi.nlm.nih.gov/28254419
Autor:
Panita Pathipvanich, Chureeratana Bowonwatanuwong, Yuwadee Buranawanitchakorn, Suporn Koetsawang, Wasna Sirirungsi, Luc Decker, Gonzague Jourdain, Marc Lallemant, Apichat Chutanunta, Sukit Banchongkit, Sophie Le Cœur, Guttiga Halue, Sylvaine Barbier, Pensiriwan Sang-a-gad, Sudanee Buranabanjasatean, Baptiste Leurent, Somboon Tansuphasawasdikul, Rittha Lertkoonalak, Federica Fregonese, Nuananong Luekamlung, Kenneth McIntosh, Sombat Thanprasertsuk, Naree Eiamsirikit, Narong Winiyakul, Naruepon Yutthakasemsunt, Patrinee Traisathit, Pakorn Wittayapraparat, Srisuda Thongbuaban, Phpt study team, Malee Techapornroong, Tim R. Cressey, Nicole Ngo-Giang-Huong, Pacharee Kantipong, Virat Klinbuayaem, Intira Jeannie Collins, Prattana Leenasirimakul, Ampaipith Nilmanat
Publikováno v:
PLoS Medicine, Vol 10, Iss 8, p e1001494 (2013)
PLoS Medicine
PLoS Medicine, Public Library of Science, 2013, 10 (8), pp.e1001494. ⟨10.1371/journal.pmed.1001494⟩
PLoS Medicine, 2013, 10 (8), pp.e1001494. ⟨10.1371/journal.pmed.1001494⟩
PLoS Medicine
PLoS Medicine, Public Library of Science, 2013, 10 (8), pp.e1001494. ⟨10.1371/journal.pmed.1001494⟩
PLoS Medicine, 2013, 10 (8), pp.e1001494. ⟨10.1371/journal.pmed.1001494⟩
Using a randomized controlled trial, Marc Lallemant and colleagues ask if a CD4-based monitoring and treatment switching strategy provides a similar clinical outcome compared to the standard viral load-based strategy for adults with HIV in Thailand.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7ba44467aaf8afc0181cfd517035f53
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23940461/?tool=EBI
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23940461/?tool=EBI
Autor:
Billy Amzal, Pensiriwan Sang-a-gad, Naree Eiamsirikit, Sripetcharat Mekviwattanawong, Rittha Lertkoonalak, Naruepon Yutthakasemsunt, Kenneth McIntosh, Yuwadee Buranawanitchakorn, Nicole Ngo-Giang-Huong, Somboon Tansuphasawasdikul, Marc Lallemant, Gonzague Jourdain
Publikováno v:
PLoS ONE
PLoS ONE, Vol 6, Iss 11, p e27427 (2011)
PLoS ONE, Vol 6, Iss 11, p e27427 (2011)
Background WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs), i.e. nevirapine or efavirenz, with lamivudine or emtricitabine, plus zidovudine or t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cfead81be6c7a4eaa220005070f550e
https://pubmed.ncbi.nlm.nih.gov/22132100
https://pubmed.ncbi.nlm.nih.gov/22132100